# US 2020/0138710 A1 · Compositions with permeation enhancers for drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138710 A1
- Document ID: US20200138710A1
- Status: Published application
- Kind: A1
- Application number: 16/333,368
- Filed: 2017-09-14
- Published: 2020-05-07
- Earliest claimed: 2016-09-14
- Assignees: Children's Medical Center Corporation
- Applicants: Children's Medical Center Corporation
- Inventors: Daniel S. Kohane; Rong Yang
- Web page: https://patentgrep.com/patent/US20200138710A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/30: Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K 9/0046: {Ear}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61P 27/16: Otologicals
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and has rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of infectious disease (e.g., otitis media). Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.

## Claims

### Claim 1

A composition comprising:
(a) a therapeutic agent or a combination of therapeutic agents;
(b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and
(c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer;
wherein:
the composition forms a gel at temperatures above a sol-gel transition temperature; and
the sol-gel transition temperature is less than about 39° C.;
and at least one of conditions (i), (ii), and (iii) are met:
(i) the sol-gel transition temperature of the composition is less than the sol-gel transition temperature of a reference composition plus about 23° C. or 39° C., whichever is greater;
(ii) the storage modulus of the composition is greater than about 13.5% of the storage modulus of the reference composition or greater than about 500 Pa, whichever is smaller, at a temperature of about 37° C.; and
(iii) the loss modulus of the composition is between about 12% and about 750% of the loss modulus of the reference composition at a temperature of about 37° C.;
wherein:
the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers;
the permeation enhancer or combination of permeation enhancers comprises between about 0.1% and 30% of the composition by weight per volume composition;
the polymer is a block copolymer comprising a poloxamer;
the poloxamer comprises between about 19% and 45% of the composition by weight per volume composition.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein conditions (i) and (ii); (i) and (iii); or (ii) and (iii) are met.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein the storage modulus is greater than about 13.5%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% of the storage modulus of the reference composition at a temperature of about 37° C.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The composition of claim 1, wherein the sol-gel transition temperature is above about 10° C., above about 20° C., above about 30° C., or above about 35° C.

### Claim at position 8

11-14. (canceled)

### Claim 15 (depends on 1)

The composition of claim 1, wherein the composition comprises, by weight of permeation enhancer per volume composition, about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 10%, 15%, 20%, 25%, or 30% permeation enhancer.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The composition of claim 1, wherein the composition comprises, by weight of poloxamer per volume composition, between about 22% and about 35% poloxamer.

### Claim at position 12

18-19. (canceled)

### Claim 20 (depends on 1)

The composition of claim 1, wherein the poloxamer is P407 or P331.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The composition of claim 1, wherein the permeation enhancer is a surfactant, terpene, amino amide, amino ester, azide-containing compound, alcohol, pyrrolidone, sulfoxide, fatty acid, peptide, or anesthetic agent.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the permeation enhancer is sodium dodecyl sulfate, decyl methyl sulfoxide, nonoxynol-9, sodium pyrrolidone carboxylate, ammonium lauryl sulfate, sodium lauryl sulfate, cetyl trimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the permeation enhancer is limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, or ethylpiperazine carboxylate.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the permeation enhancers include:
an anesthetic permeation enhancer;
and surfactant and terpene permeation enhancers,
wherein the anesthetic permeation enhancer boosts the enhancement of the flux of the therapeutic agent by the surfactant and terpene permeation enhancers across the barrier.

### Claim at position 19

26-29. (canceled)

### Claim 30 (depends on 1)

The composition of claim 1, wherein the permeation enhancer is sodium dodecyl sulfate, limonene, or combinations thereof.

### Claim at position 21

31-32. (canceled)

### Claim 33 (depends on 1)

The composition of claim 1, wherein the therapeutic agent is an antimicrobial agent, antibiotic agent, anesthetic agent, anti-inflammatory agent, analgesic agent, anti-fibrotic agent, anti-sclerotic agent, anticoagulant agent, or diagnostic agent.

### Claim at position 23

34-40. (canceled)

### Claim 41 (depends on 1)

The composition of claim 1, wherein the composition forms a gel at a sol-gel transition temperature between about 0° C. and about 39° C.

### Claim 42

A composition comprising:
(a) a therapeutic agent or a combination of therapeutic agents;
(b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and
(c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer;
wherein:
the composition forms a gel at temperatures above a sol-gel transition temperature; and
the sol-gel transition temperature is less than about 39° C.;
and at least one of conditions (i), (ii), and (iii) are met:
(i) the sol-gel transition temperature of the composition is less than the sol-gel transition temperature of a reference composition plus about 23° C. or 39° C., whichever is greater;
(ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition or greater than about 500 Pa, whichever is smaller, at a temperature of about 37° C.; and
(iii) the loss modulus of the composition is between about 12% and about 750% of the loss modulus of the reference composition at a temperature of about 37° C.;
wherein:
the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers;
the permeation enhancer or combination of permeation enhancers comprises sodium dodecyl sulfate and limonene, and
the permeation enhancer or combination of permeation enhancers comprises between about 3% and 6% of the composition by weight per volume composition;
the polymer is a block copolymer comprising poloxamer P407; and
the P407 comprises between about 22% and about 27% of the composition by weight per volume composition.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

A method of treating a disease, comprising administering a composition of claim 1, to a subject in need thereof.

### Claim 45

(canceled)

### Claim 46 (depends on 44)

The method of claim 44, wherein the disease is an infection or an infectious disease.

### Claim at position 30

47-50. (canceled)

### Claim 51 (depends on 1)

A method of eradicating a biofilm, comprising administering a composition of claim 1, to a subject in need thereof.

### Claim 52 (depends on 1)

A method of delivering a composition of claim 1, the method comprising administering the composition to an ear canal of a subject, wherein the composition contacts the surface of a tympanic membrane.

### Claim at position 33

53-63. (canceled)

### Claim 64 (depends on 1)

A kit for treating an infectious disease comprising a container, a composition of claim 1, and instructions for administering the composition to a subject in need thereof.

### Claim at position 35

65-67. (canceled)
